|
Volumn 370, Issue 4, 2014, Pages 383-384
|
The authors reply
|
Author keywords
[No Author keywords available]
|
Indexed keywords
DABIGATRAN;
WARFARIN;
ANTICOAGULANT AGENT;
BENZIMIDAZOLE DERIVATIVE;
BETA ALANINE;
DRUG DERIVATIVE;
ANTICOAGULANT THERAPY;
ANTICOAGULATION;
COMPETITIVE INHIBITION;
DRUG EFFICACY;
DRUG MONITORING;
DRUG SAFETY;
HEART VALVE REPLACEMENT;
HUMAN;
KIDNEY FUNCTION;
LETTER;
MECHANICAL HEART VALVE;
OUTCOME ASSESSMENT;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
THROMBIN TIME;
TREATMENT INDICATION;
CEREBROVASCULAR ACCIDENT;
FEMALE;
HEART ATRIUM FIBRILLATION;
HEART VALVE PROSTHESIS;
MALE;
NOTE;
THROMBOEMBOLISM;
ANTICOAGULANTS;
ATRIAL FIBRILLATION;
BENZIMIDAZOLES;
BETA-ALANINE;
FEMALE;
HEART VALVE PROSTHESIS;
HUMANS;
MALE;
STROKE;
THROMBOEMBOLISM;
WARFARIN;
|
EID: 84892712648
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1315004 Document Type: Letter |
Times cited : (8)
|
References (1)
|